Skip to main content
Gland Pharma Limited logo

Gland Pharma Limited — Investor Relations & Filings

Ticker · GLAND ISIN · INE068V01023 LEI · 335800JJVDY5R6KF5K34 BSE.NS Manufacturing
Open in API
Filings indexed 676 across all filing types
Latest filing 2026-05-15 Regulatory Filings
Country IN India
Listing BSE.NS GLAND

About Gland Pharma Limited

https://glandpharma.com

Gland Pharma Limited is a specialized Contract Development and Manufacturing Organization (CDMO) focused on injectable formulations. The company operates primarily through a business-to-business (B2B) model, providing development and manufacturing services for a diverse range of sterile injectables. Its portfolio encompasses complex generics across various therapeutic areas, including oncology, ophthalmology, anti-infectives, and orthopedics. Gland Pharma maintains a vertically integrated supply chain, ensuring control over critical raw materials and active pharmaceutical ingredients. The company serves a global market, with a significant presence in regulated regions such as the United States, Europe, Canada, and Australia. Its manufacturing facilities adhere to international quality standards and hold approvals from major regulatory bodies. Key strengths include expertise in niche segments like heparin and enoxaparin, alongside a robust pipeline of complex delivery systems.

Recent filings

Filing Released Lang Actions
Updates
Regulatory Filings Classification · 81% confidence The document is a formal notice filed to stock exchanges under SEBI Listing Regulations confirming outcomes of a Board meeting held on May 15, 2026. It approves and encloses Audited Financial Results (standalone and consolidated) for year ended March 31, 2026 along with the Auditor’s Report, declaration from CFO, press release, and investor presentation. It also recommends a final dividend and sets the record date, and announces the date of the 48th AGM. This is not the full Annual Report (10-K), nor a quarterly or interim report (IR), nor simply a notice of dividend (DIV). It is an exchange filing of the Board meeting’s outcomes and audited yearly results pursuant to SEBI regulations. It is not limited to a shareholding or board change, nor is it a pure earnings release (ER) or investor presentation (IP), and not a management change (MANG). As it does not neatly fit into any specialized category except as a general regulatory announcement, it should be classified under Regulatory Filings (RNS).
2026-05-15 English
Record Date
Report Publication Announcement Classification · 85% confidence The document is a formal board meeting outcome notice submitted to stock exchanges. It does not itself present detailed financial statements, but announces that the Board has approved and enclosed the audited financial results, audit report, press release and investor presentation, together with dividend recommendations and AGM date. This fits the definition of a Report Publication Announcement (RPA) – an announcement regarding the release or publication of company reports. It is not the full annual report or earnings release itself, nor a management change or dividend notice in isolation.
2026-05-15 English
The 48th AGM of the Company will be held on August 25, 2026
Audit Report / Information Classification · 91% confidence The document is the formal Outcome of the Board Meeting filed under regulation 33 of SEBI LODR to announce and enclose the Audited Financial Results for the year/quarter ended March 31, 2026 together with the Independent Auditor’s Report (unmodified opinion). It includes the full Auditor’s Report on the consolidated financial results and review of quarterly results, not simply an announcement or summary. This aligns with our “Audit Report / Information” category (Code: AR). FY 2026
2026-05-15 English
Board fixes Record date of August 11, 2026 for the Final Dividend
Audit Report / Information Classification · 85% confidence The document is a board meeting outcome notice under SEBI LODR, reporting the approval of audited standalone and consolidated financial results for the year ended March 31, 2026 (pursuant to Regulation 33) and including the Independent Auditor’s Report on those annual consolidated results (and reviewed quarterly results). Although it is sent to stock exchanges as a regulatory disclosure, it contains the actual audit report rather than merely announcing a report’s publication. This matches the definition of Audit Report / Information (AR). FY 2026
2026-05-15 English
Board approves final dividend of Rs. 20/- per share, subject to approval of shareholders in the ensuing 48th AGM
Audit Report / Information Classification · 85% confidence The document is an outcome of a Board Meeting under SEBI LODR Regulation 33, which attaches and publishes the full Independent Auditor’s Report on the audited standalone and consolidated financial results for the year ended March 31, 2026 (with opinion and review conclusion). It is not a full Annual Report (10-K) nor a simple press release (ER) or investor presentation (IP), nor is it merely announcing a report’s publication (RPA). Instead, the core substantive content is the standalone audit report itself. Therefore, it best fits the “Audit Report / Information” category (AR). FY 2026
2026-05-15 English
Press Release on Q4FY26 Audited Financial Results
Earnings Release Classification · 92% confidence The document is a press release under SEBI LODR Regulation 30 announcing Gland Pharma’s Q4 FY26 financial results, including key revenue and profit highlights, summary tables, dividend recommendation, and earnings call details. It is not the full statutory interim report but the initial market announcement of quarterly financials, fitting the Earnings Release category. Q4 2026
2026-05-15 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.